- Home
- TLSA vs CUE Comparison
TLSA vs CUE Comparison
Compare TLSA & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- CUE
- Stock Information
- Founded
- TLSA 2013
- CUE 2014
- Country
- TLSA United Kingdom
- CUE United States
- Employees
- TLSA N/A
- CUE N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- CUE Health Care
- Exchange
- TLSA Nasdaq
- CUE Nasdaq
- Market Cap
- TLSA 187.0M
- CUE 48.0M
- IPO Year
- TLSA 2000
- CUE 2018
- Fundamental
- Price
- TLSA $1.46
- CUE $0.75
- Analyst Decision
- TLSA
- CUE Strong Buy
- Analyst Count
- TLSA 0
- CUE 3
- Target Price
- TLSA N/A
- CUE $3.00
- AVG Volume (30 Days)
- TLSA 256.5K
- CUE 308.2K
- Earning Date
- TLSA 07-15-2025
- CUE 08-13-2025
- Dividend Yield
- TLSA N/A
- CUE N/A
- EPS Growth
- TLSA N/A
- CUE N/A
- EPS
- TLSA N/A
- CUE N/A
- Revenue
- TLSA N/A
- CUE $7,991,000.00
- Revenue This Year
- TLSA N/A
- CUE N/A
- Revenue Next Year
- TLSA N/A
- CUE $23.84
- P/E Ratio
- TLSA N/A
- CUE N/A
- Revenue Growth
- TLSA N/A
- CUE 13.83
- 52 Week Low
- TLSA $0.63
- CUE $0.45
- 52 Week High
- TLSA $1.91
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- TLSA 45.58
- CUE 57.89
- Support Level
- TLSA $1.43
- CUE $0.65
- Resistance Level
- TLSA $1.81
- CUE $0.88
- Average True Range (ATR)
- TLSA 0.09
- CUE 0.07
- MACD
- TLSA -0.02
- CUE 0.01
- Stochastic Oscillator
- TLSA 6.89
- CUE 62.51
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.